• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Nithya Subramanian

THE 50:50 joint venture between Chiron Vaccines and Panacea would be benefited if Novartis finally picks up the balance equity in the US-based company, said Mr Rajesh Jain, Joint Managing Director, Panacea Biotec.

Though Chiron has rejected Novartis' offer of picking up the remaining equity at $40 a share, Mr Jain said that if any such deal came through, there would be no impact on its joint venture. Novartis currently has over a 42 per cent stake in Chiron and analysts feel that this would give Novartis access to a range of vaccines.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Gujarat NRE launches portal for coal trading

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line